Cargando…
Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
BACKGROUND: Inflammation plays an essential role in secondary brain injury after intracerebral hemorrhage (ICH). Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) have been suggested to suppress neuroinflammation after central nervous system (CNS) damage in...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881796/ https://www.ncbi.nlm.nih.gov/pubmed/33603374 http://dx.doi.org/10.2147/NDT.S291624 |
_version_ | 1783650952309374976 |
---|---|
author | Zhang, Chao Zhong, Jun Chen, Wei-Xiang Zhang, Xu-Yang Li, Yu-Hong Zhou, Teng-Yuan Zou, Yong-Jie Lan, Chuan Li, Lan Lai, Zhao-Pan Feng, Hua Hu, Rong |
author_facet | Zhang, Chao Zhong, Jun Chen, Wei-Xiang Zhang, Xu-Yang Li, Yu-Hong Zhou, Teng-Yuan Zou, Yong-Jie Lan, Chuan Li, Lan Lai, Zhao-Pan Feng, Hua Hu, Rong |
author_sort | Zhang, Chao |
collection | PubMed |
description | BACKGROUND: Inflammation plays an essential role in secondary brain injury after intracerebral hemorrhage (ICH). Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) have been suggested to suppress neuroinflammation after central nervous system (CNS) damage in animal models. However, the role of ACEIs and ARBs in ICH patients with hypertension remains unresolved in clinic. The aim of the present study is to evaluate the effect of ACEIs/ARBs on ICH patients with hypertension using a retrospective, single-center data analysis. METHODS: ICH patients diagnosed by computerized tomographic (CT) at Southwest Hospital, Third Military Medical University were included in the present research from January 2015 to December 2019. According to the medical history for the usage of antihypertensive drugs, patients were assigned into either ACEIs/ARBs group or non-ACEIs/ARBs group. Demographics, clinical baseline, radiological documents and treatments were collected and these data were statistically analyzed between the two groups. RESULTS: A total of 635 ICH patients with hypertension were included and allocated into 2 groups according to the usage of antihypertensive drugs: 281 in the ACEIs/ARBs group and 354 in the non-ACEIs/ARBs group. The results presented that the 3-months mortality and prevalence of ICH-associated pneumonia were lower in ACEIs/ARBs group than that in non-ACEIs/ARBs group (5.0% vs 11.9%, p=0.002; 58.4% vs 66.7%, p=0.031). While, there was no significant difference in favorable outcome (40.2% vs 33.9%, p=0.101) between the two groups. Furthermore, patients in ACEIs/ARBs group exhibited significantly less perihematomal edema volume on days 3 (23.5 ± 14.4 versus 28.7 ± 20.1 mL, p=0.045) and 7 (21.0 ± 13.7 versus 25.7 ± 17.6 mL, p=0.044), compared to that in non- ACEIs/ARBs group. CONCLUSION: The usage of ACEIs/ARBs helps decrease mortality, perihematomal edema volume, and prevalence of ICH-associated pneumonia in ICH patients with hypertension. |
format | Online Article Text |
id | pubmed-7881796 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-78817962021-02-17 Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage Zhang, Chao Zhong, Jun Chen, Wei-Xiang Zhang, Xu-Yang Li, Yu-Hong Zhou, Teng-Yuan Zou, Yong-Jie Lan, Chuan Li, Lan Lai, Zhao-Pan Feng, Hua Hu, Rong Neuropsychiatr Dis Treat Original Research BACKGROUND: Inflammation plays an essential role in secondary brain injury after intracerebral hemorrhage (ICH). Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) have been suggested to suppress neuroinflammation after central nervous system (CNS) damage in animal models. However, the role of ACEIs and ARBs in ICH patients with hypertension remains unresolved in clinic. The aim of the present study is to evaluate the effect of ACEIs/ARBs on ICH patients with hypertension using a retrospective, single-center data analysis. METHODS: ICH patients diagnosed by computerized tomographic (CT) at Southwest Hospital, Third Military Medical University were included in the present research from January 2015 to December 2019. According to the medical history for the usage of antihypertensive drugs, patients were assigned into either ACEIs/ARBs group or non-ACEIs/ARBs group. Demographics, clinical baseline, radiological documents and treatments were collected and these data were statistically analyzed between the two groups. RESULTS: A total of 635 ICH patients with hypertension were included and allocated into 2 groups according to the usage of antihypertensive drugs: 281 in the ACEIs/ARBs group and 354 in the non-ACEIs/ARBs group. The results presented that the 3-months mortality and prevalence of ICH-associated pneumonia were lower in ACEIs/ARBs group than that in non-ACEIs/ARBs group (5.0% vs 11.9%, p=0.002; 58.4% vs 66.7%, p=0.031). While, there was no significant difference in favorable outcome (40.2% vs 33.9%, p=0.101) between the two groups. Furthermore, patients in ACEIs/ARBs group exhibited significantly less perihematomal edema volume on days 3 (23.5 ± 14.4 versus 28.7 ± 20.1 mL, p=0.045) and 7 (21.0 ± 13.7 versus 25.7 ± 17.6 mL, p=0.044), compared to that in non- ACEIs/ARBs group. CONCLUSION: The usage of ACEIs/ARBs helps decrease mortality, perihematomal edema volume, and prevalence of ICH-associated pneumonia in ICH patients with hypertension. Dove 2021-02-09 /pmc/articles/PMC7881796/ /pubmed/33603374 http://dx.doi.org/10.2147/NDT.S291624 Text en © 2021 Zhang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Zhang, Chao Zhong, Jun Chen, Wei-Xiang Zhang, Xu-Yang Li, Yu-Hong Zhou, Teng-Yuan Zou, Yong-Jie Lan, Chuan Li, Lan Lai, Zhao-Pan Feng, Hua Hu, Rong Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage |
title | Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage |
title_full | Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage |
title_fullStr | Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage |
title_full_unstemmed | Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage |
title_short | Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage |
title_sort | usage of angiotensin-converting enzyme inhibitor or angiotensin ii receptor blocker in hypertension intracerebral hemorrhage |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881796/ https://www.ncbi.nlm.nih.gov/pubmed/33603374 http://dx.doi.org/10.2147/NDT.S291624 |
work_keys_str_mv | AT zhangchao usageofangiotensinconvertingenzymeinhibitororangiotensiniireceptorblockerinhypertensionintracerebralhemorrhage AT zhongjun usageofangiotensinconvertingenzymeinhibitororangiotensiniireceptorblockerinhypertensionintracerebralhemorrhage AT chenweixiang usageofangiotensinconvertingenzymeinhibitororangiotensiniireceptorblockerinhypertensionintracerebralhemorrhage AT zhangxuyang usageofangiotensinconvertingenzymeinhibitororangiotensiniireceptorblockerinhypertensionintracerebralhemorrhage AT liyuhong usageofangiotensinconvertingenzymeinhibitororangiotensiniireceptorblockerinhypertensionintracerebralhemorrhage AT zhoutengyuan usageofangiotensinconvertingenzymeinhibitororangiotensiniireceptorblockerinhypertensionintracerebralhemorrhage AT zouyongjie usageofangiotensinconvertingenzymeinhibitororangiotensiniireceptorblockerinhypertensionintracerebralhemorrhage AT lanchuan usageofangiotensinconvertingenzymeinhibitororangiotensiniireceptorblockerinhypertensionintracerebralhemorrhage AT lilan usageofangiotensinconvertingenzymeinhibitororangiotensiniireceptorblockerinhypertensionintracerebralhemorrhage AT laizhaopan usageofangiotensinconvertingenzymeinhibitororangiotensiniireceptorblockerinhypertensionintracerebralhemorrhage AT fenghua usageofangiotensinconvertingenzymeinhibitororangiotensiniireceptorblockerinhypertensionintracerebralhemorrhage AT hurong usageofangiotensinconvertingenzymeinhibitororangiotensiniireceptorblockerinhypertensionintracerebralhemorrhage |